Radulović J, Djergović D, Miljević C, Janković B D
Immunology Research Center, Belgrade, Yugoslavia.
Neuroimmunomodulation. 1994 Jul-Aug;1(4):236-41. doi: 10.1159/000097171.
The present study deals with the influence of preferential kappa-opioid agonist MR 2034 on experimental allergic encephalomyelitis (EAE). For this purpose, 9-week-old male Dark August rats were treated intraperitoneally with 0.2 mg/kg of MR 2034 as follows: (a) from the day of EAE induction until sacrifice; (b) from the day of EAE induction until the appearance of neurological signs, and (c) from the appearance of neurological signs until sacrifice. Repeated injections of MR 2034 given during the whole period of observation produced the most pronounced suppression of EAE clinical signs, histological lesions in the brain and spinal cord, and anti-myelin basic protein antibody production. These results suggest that kappa-opioid receptors may be involved in the development of EAE.
本研究探讨了选择性κ-阿片受体激动剂MR 2034对实验性变态反应性脑脊髓炎(EAE)的影响。为此,对9周龄雄性Dark August大鼠腹腔注射0.2 mg/kg的MR 2034,给药方式如下:(a)从EAE诱导之日起直至处死;(b)从EAE诱导之日起直至出现神经症状;(c)从出现神经症状起直至处死。在整个观察期内重复注射MR 2034对EAE临床症状、脑和脊髓的组织学损伤以及抗髓鞘碱性蛋白抗体的产生产生了最显著的抑制作用。这些结果表明,κ-阿片受体可能参与了EAE的发病过程。